Claims for Patent: 9,814,767
✉ Email this page to a colleague
Summary for Patent: 9,814,767
Title: | Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide |
Abstract: | This document provides methods and materials for generating CD8.sup.+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an SLAFLPESFD amino acid sequence in vivo or in vitro to generate CD8.sup.+ T cells having the ability to recognize and lyse cancer cells expressing a HER2/neu polypeptide are provided. |
Inventor(s): | Knutson; Keith L. (Fort Pierce, FL), Henle; Andrea M. (Cambridge, MA) |
Assignee: | Mayo Foundation for Medical Education and Research (Rochester, MN) |
Application Number: | 14/379,150 |
Patent Claims: | 1. A composition comprising a polypeptide, wherein the sequence of said polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1, wherein said polypeptide is
immunogenic, and wherein said composition comprises an adjuvant and an agent selected from the group consisting of IL-2, GM-CSF, and rintatolimod.
2. The composition of claim 1, wherein said adjuvant is an oil and water mixture. 3. The composition of claim 1, wherein said adjuvant is Montanide ISA-51. 4. The composition of claim 1, wherein said agent is IL-2. 5. A method for increasing the number of CD8.sup.+ T cells having the ability to kill breast cancer cells expressing a HER2/neu polypeptide, wherein said method comprises contacting a population of CD8.sup.+ T cells with a polypeptide and an agent selected from the group consisting of IL-2, GM-CSF, and rintatolimod, wherein the sequence of said polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1. 6. The method of claim 5, wherein said contacting step occurs in an ex vivo manner. 7. The method of claim 5, wherein said contacting step occurs in an in vivo manner. 8. A method for increasing, within a human, the number of CD8.sup.+ T cells having the ability to kill breast cancer cells expressing a HER2/neu polypeptide, wherein said method comprises administering a composition to said human, wherein said composition comprises a polypeptide and an agent selected from the group consisting of IL-2, GM-CSF, and rintatolimod, wherein the sequence of said polypeptide consists of the amino acid sequence set forth in SEQ ID NO:1. 9. The method of claim 8, wherein said human contains breast cancer cells expressing said HER2/neu polypeptide. 10. The method of claim 8, wherein said composition comprises an adjuvant. 11. The method of claim 10, wherein said adjuvant is an oil and water mixture. 12. The method of claim 10, wherein said adjuvant is Montanide ISA-51. 13. The method of claim 8, wherein said agent is IL-2. 14. The method of claim 8, wherein said agent is GM-CSF. 15. The method of claim 8, wherein said method further comprises administering trastuzumab to said human. |
Details for Patent 9,814,767
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-02-17 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-02-17 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2032-02-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.